Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
Clinical trial NCT04995094 · WITHDRAWN
Trial details
- NCT number
- NCT04995094
- Sponsor
- HiberCell, Inc.
- Status
- WITHDRAWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-15
- Primary completion
- 2023-02-18
- Enrollment
- 0
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.